| 货号 | 18234-50mg |
| 描述 | Pramipexole (Item No. 11981) is an agonist of dopamine receptors that has applications in Parkinson’s disease and other disorders.1,2,3,4 Pramipexole is usually available as a mixture of enantiomers, with the majority of the dopamine receptor-dependent activity resulting from the (S) form.5 (R)-Pramipexole is an enantiomer of pramipexole that is ~100-fold less active than the (S) form as a dopamine receptor agonist.5,6 For this reason, it can be used as a negative control for the (S) form in the study of dopamine receptors. Both isoforms are antioxidants that target mitochondria to prevent apoptosis.5,7,8,9 This cytoprotective effect of (R)-pramipexole, without dopaminergic side effects, suggests utility in amyotrophic lateral sclerosis.5,10 |
| 别名 | Dexpramipexole;KNS 760704;(+)-Pramipexole;SND 919CL2X; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Hametner, E.M.,Seppi, K., and Poewe, W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease. Clinical Interventions in Aging 7, 83-88 (2012). 2.Kvernmo, T.,Härtter, S., and Bürger, E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clinical Therapeutics 28(8), 1065-1078 (2006). 3.Millan, M.J.,Maiofiss, L.,Cussac, D., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 303(2), 791-804 (2002). 4.Newman-Tancredi, A.,Cussac, D.,Audinot, V., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor. Journal of Pharmacology and Experimental Therapeutics 303(2), 805-814 (2002). 5.Danzeisen, R.,Schwalenstoecker, B.,Gillardon, F., et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. JPET 316(1), 189-199 (2006). 6.Chang, W.I.,Weber, M.,Breier, M.R., et al. Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Research 1437, 69-76 (2012). 7.Ferrari-Toninelli, G.,Maccarinelli, G.,Uberti, D., et al. Mitochondria-targeted antioxidant effects of S(−) and R(+) pramipexole. BMC Pharmacology 10(2), 1-6 (2010). 8.Abramova, N.A.,Cassarino, D.S.,Khan, S.M., et al. Inhibition by R(+) or S(−) pramipexole of caspase activation and cell death induced by methylpyridinium ion orβamyloid peptide in SH-SY5Y neuroblastoma. Journal of Neuroscience Research 67(4), 494-500 (2002). 9.Gu, M.,Iravani, M.M.,Cooper, J.M., et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry 91(5), 1075-1081 (2004). 10.Cheah, B.C., and Kiernan, M.C. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 13(12), 911-920 (2010). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 284.2 |
| 分子式 | C10H17N3S • 2HCl |
| CAS号 | 104632-27-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |